

patients who discontinued were still in remission almost 10 months after withdrawal. Thus, stopping the drug in patients who are in remission remains an option. However, better predictors for outcomes of patients who flare on drug holiday are needed. Whether ASDAS values in the low range work in this regard needs further study. Unfortunately, a third group in which the dose was reduced or the interval of injections prolonged was not part of this study. This, however, is already frequently done in clinical practice and should be investigated in the future. The fact that many patients who reported clinical flares had normal CRP levels at that timepoint also needs further study.

When these results are taken together, this study is important because it shows, on the basis of appropriate methodology, that continuation of a TNF inhibitor has superior outcomes than discontinuation, and this was only true for patients who had reached a state of inactive disease after 24 weeks of TNF inhibitor therapy. However, with almost 50% of patients achieving drug-free remission, the health system could possibly save a lot of money, but how this strategy would influence the future course of the disease is not known. Finally, the same study in ankylosing spondylitis—which has not been done to date—is likely to have different results, with a lower proportion of patients in drug-free remission, because patients of a similar age with radiographic axial spondyloarthritis have a higher burden of inflammation, even though they report similar pain levels.

Jürgen Braun

Rheumazentrum Ruhrgebiet, Herne 44649, Germany; and Department of Rheumatology, Ruhr University Bochum, Bochum, Germany  
juergen.braun@elisabethgruppe.de

I declare no competing interests.

- 1 Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009; **68**: 777–83.
- 2 Deodhar A, Strand V, Kay J, Braun J. The term “non-radiographic axial spondyloarthritis” is much more important to classify than to diagnose patients with axial spondyloarthritis. *Ann Rheum Dis* 2016; **75**: 791–94.
- 3 Sieper J, Poddubnyy D. Axial spondyloarthritis. *Lancet* 2017; **390**: 73–84.
- 4 Kiltz U, Baraliakos X, Karakostas P, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? *Arthritis Care Res (Hoboken)* 2012; **64**: 1415–22.
- 5 Wang R, Gabriel SE, Ward MM. Progression of nonradiographic axial spondyloarthritis to ankylosing spondylitis: a population-based cohort study. *Arthritis Rheumatol* 2016; **68**: 1415–21.
- 6 Wang R, Crowson CS, Wright K, Ward MM. Clinical evolution in patients with new-onset inflammatory back pain: a population-based cohort study. *Arthritis Rheumatol* 2018; published online Feb 22. DOI:10.1002/art.40460.
- 7 Poddubnyy D, Haibel H, Braun J, Rudwaleit M, Sieper J. Brief report: clinical course over two years in patients with early nonradiographic axial spondyloarthritis and patients with ankylosing spondylitis not treated with tumor necrosis factor blockers: results from the German Spondyloarthritis Inception Cohort. *Arthritis Rheumatol* 2015; **67**: 2369–75.
- 8 Landewé R, Sieper J, Mease P, et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. *Lancet* 2018; published online June 28. [http://dx.doi.org/10.1016/S0140-6736\(18\)31362-X](http://dx.doi.org/10.1016/S0140-6736(18)31362-X).
- 9 Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005; **7**: R439–44.
- 10 Song IH, Althoff CE, Haibel H, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. *Ann Rheum Dis* 2012; **71**: 1212–15.



## Improving management of neonatal infections

Published Online  
July 6, 2018

[http://dx.doi.org/10.1016/S0140-6736\(18\)31432-6](http://dx.doi.org/10.1016/S0140-6736(18)31432-6)

See [Articles](#) page 145

Infections causing sepsis, meningitis, or pneumonia contributed directly to around 0.6 million neonatal deaths worldwide in 2016,<sup>1</sup> and indirectly to many more through pathways leading to preterm birth and neonatal encephalopathy. Despite this knowledge, understanding of the causes of neonatal infection, particularly in resource-poor settings, is limited. Treatment in these settings usually relies on the sensitive but non-specific clinical diagnosis of possible serious bacterial infection (pSBI),<sup>2</sup> made by front-line health-care workers and defined according to set criteria. Of the almost 7 million neonates needing treatment worldwide each year based on this diagnosis,<sup>3</sup> most are not tested for specific


infectious causes and many are likely to have non-infectious conditions (figure).

In *The Lancet*, Samir Saha and colleagues report the Aetiology of Neonatal Infection in South Asia (ANISA) study,<sup>4</sup> which is an important step forward in understanding the infectious causes of neonatal pSBI. The community-based study design is an advance on previous studies, which have been mostly facility-based, and often performed limited microbiological investigations. ANISA enrolled 84 971 mothers antenatally across five sites in Bangladesh, India, and Pakistan, and used community health-care workers to follow up neonates after birth. Antenatal

recruitment of mothers meant that neonates who died shortly after birth were counted and that pSBIs were quickly identified by community health-care worker follow-up. Systematic sampling and testing with conventional and molecular laboratory methods maximised pathogen detection. Reductions in specificity of diagnosis and identification of multiple organisms by molecular diagnostics were mitigated by use of control data and Bayesian partially latent class modelling to estimate attributable proportions for specific infectious causes.

Saha and colleagues' findings for the causes of pSBIs and the non-specificity of this classification as a diagnosis are important. Of 6022 pSBI episodes, only 16% had attributed bacterial causes, and 102 (2%) of 4859 tested blood samples had clinically significant pathogens isolated by culture. More specific clinical algorithms and point-of-care diagnostics are needed to direct antibiotic treatment to those who need it, especially as antibiotic treatment for neonatal pSBI is scaled up; WHO guidelines recommend that when referral to hospital is not possible, antibiotic treatment should be given to outpatients to expand access to care.<sup>5</sup> Of note, however, this recommendation was informed by pragmatic antibiotic trials that used pSBI as a clinical diagnosis and tested equivalence of regimens.<sup>6-8</sup> The ANISA study findings add to concerns about the use of non-specific clinical diagnoses for such trials<sup>9</sup> and underscore the uncertainty in their findings.

As well as what it found, ANISA is important for what it did not find. Among 71361 livebirths, 3061 (4%) babies died by the end of follow-up, most of these soon after birth. Despite active follow-up by community health-care workers, only 689 (23%) babies who died were assessed by a physician before death, and only 349 (11%) had samples taken in the 7 days before death.<sup>4</sup> Under-representation of deaths is a limitation in terms of attributing infectious causes, but showing how many neonates who die and who are not seen or investigated for infection is important. These data are often not captured, or are not reported, and the extent to which the sickest neonates in the community, in research or in clinical practice, are not seen is unknown in many resource-poor settings. Improving understanding of the causes of these deaths is crucial. Infection is likely to be an important direct and indirect contributor, as are preterm birth and



**Figure: Overlap between possible serious bacterial infections and other clinical syndromes**  
Reproduced from Seale et al.<sup>3</sup>

neonatal encephalopathy. In ANISA, the number of attributed infections was nearly double that among babies who died than among those who survived, and more than 90% of the infectious causes in those who died were bacterial.<sup>4</sup>

Further development of the evidence base to better direct interventions towards the highest burden of neonatal mortality at and in the few days after birth will need new approaches. One such approach is post-mortem investigation with minimally invasive tissue sampling, which may be more acceptable than complete diagnostic autopsy and could allow investigation of stillbirths and neonates not seen or assessed before death.<sup>10</sup> The Child Health and Mortality Prevention Surveillance study aims to use such techniques.<sup>11</sup> Another potential approach is the use of maternal vaccines in the context of trials, and surveillance after implementation, to determine the contributions of specific infectious causes. Maternal vaccines are being developed for various pathogens, such as respiratory syncytial virus and group B streptococcus.<sup>12</sup>

The ANISA study has advanced understanding of neonatal infection and highlighted the limitations of current management strategies. Ways to address these issues must be urgently sought, and it must be remembered that the neonates not seen matter as much as those that are.

\*Anna C Seale, Ramesh Agarwal

Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London WC1E 7HT, UK (ACS); College of Health and Medical Sciences, Haramaya University, Haramaya, Ethiopia (ACS); KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya (ACS); and Newborn Health Knowledge Centre, WHO Collaborating Centre for Training and Research in Newborn Care, Neonatal Division at the Department of Paediatrics, All India Institute of Medical Sciences, New Delhi, India (RA)  
anna.seale@lshtm.ac.uk


We declare no competing interests.

Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

- 1 Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 2000–15: an updated systematic analysis with implications for the Sustainable Development Goals. *Lancet* 2016; **388**: 3027–35.
- 2 Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness in children under age 2 months: a multicentre study. *Lancet* 2008; **371**: 135–42.
- 3 Seale AC, Blencowe H, Manu AA, et al. Estimates of possible severe bacterial infection in neonates in sub-Saharan Africa, south Asia, and Latin America for 2012: a systematic review and meta-analysis. *Lancet Infect Dis* 2014; **14**: 731–41.
- 4 Saha SK, Schrag SJ, El Arifeen S, et al. Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study. *Lancet* 2018; published online July 6. [http://dx.doi.org/10.1016/S0140-6736\(18\)31127-9](http://dx.doi.org/10.1016/S0140-6736(18)31127-9).
- 5 WHO. Guideline: managing possible serious bacterial infection in young infants when referral is not feasible. 2015. [http://www.who.int/maternal\\_child\\_adolescent/documents/bacterial-infection-infants/en/](http://www.who.int/maternal_child_adolescent/documents/bacterial-infection-infants/en/) (accessed June 27, 2018).
- 6 Baqui AH, Saha SK, Ahmed AS, et al. Safety and efficacy of alternative antibiotic regimens compared with 7 day injectable procaine benzylpenicillin and gentamicin for outpatient treatment of neonates and young infants with clinical signs of severe infection when referral is not possible: a randomised, open-label, equivalence trial. *Lancet Glob Health* 2015; **3**: e279–87.
- 7 Mir F, Nisar I, Tikmani SS, et al. Simplified antibiotic regimens for treatment of clinical severe infection in the outpatient setting when referral is not possible for young infants in Pakistan (Simplified Antibiotic Therapy Trial [SATT]): a randomised, open-label, equivalence trial. *Lancet Glob Health* 2017; **5**: e177–85.
- 8 Tshetu A, Lokangaka A, Ngaima S, et al. Simplified antibiotic regimens compared with injectable procaine benzylpenicillin plus gentamicin for treatment of neonates and young infants with clinical signs of possible serious bacterial infection when referral is not possible: a randomised, open-label, equivalence trial. *Lancet* 2015; **385**: 1767–76.
- 9 Mulholland K, Carlin JB, Duke T, Weber M. The challenges of trials of antibiotics for pneumonia in low-income countries. *Lancet Respir Med* 2014; **2**: 952–54.
- 10 Bassat Q, Castillo P, Martinez MJ, et al. Validity of a minimally invasive autopsy tool for cause of death determination in pediatric deaths in Mozambique: an observational study. *PLoS Med* 2017; **14**: e1002317.
- 11 Farag TH, Koplan JP, Breiman RF, et al. Precisely tracking childhood death. *Am J Trop Med Hyg* 2017; **97**: 3–5.
- 12 Sobanjo-Ter Meulen A, Abramson J, Mason E, et al. Path to impact: a report from the Bill and Melinda Gates Foundation convening on maternal immunization in resource-limited settings; Berlin—January 29–30, 2015. *Vaccine* 2015; **33**: 6388–95.



## How Montgomery is reconfiguring consent in the UK



Shutterstock/Getty Images

How should consent be measured? The answer to that question will depend on where in the world you practise medicine or receive treatment—whether it be in a patient-centred health-care service like in Australia or a more consumer-driven system such as in the USA. In the UK, the validity of consent was until recently based on whether a reasonable body of medical opinion would agree with it—a principle widely known as the Bolam test.<sup>1</sup> However, in a 2015 ruling involving a case of birth complicated by shoulder dystocia that resulted in a child being born with cerebral palsy (*Montgomery v Lanarkshire Health Board* 2015),<sup>2</sup> the UK Supreme Court declared the Bolam test to be an outdated instance of medical paternalism. The Montgomery ruling established that doctors must ensure patients are aware of any material risks involved in a proposed treatment, and of reasonable alternatives. Similar to the Australian *Canterbury v Spence* case of 1972,<sup>3</sup> the test of materiality was defined as whether a reasonable person in the patient’s position would be likely to attach significance to the risk, given their individual circumstances. In contrast to the Bolam principle, under Montgomery the focus lies with the patient and their viewpoint—they

are now the yardstick by which consent is measured. Naturally, this requires an understanding on the part of the clinician of what would be deemed a material risk to them. The Montgomery standard is being applied in the courts and in 2017, for the first time, the Appeal Court overturned a High Court judgment based on the updated law.<sup>4</sup>

The Montgomery ruling aimed to guide the medical profession towards a new model of shared decision making;<sup>5</sup> however, doctors are still working out what the ruling means in practice.<sup>6,7</sup> A 2017 literature search by one of us (NH) found that no published studies had assessed whether the judgment was changing clinical practice.<sup>8</sup> One study had explored knowledge of consent law and understanding of the relevant changes post Montgomery at a large UK teaching hospital, finding that most medical staff were not familiar with the concept of material risk and recent legal developments.<sup>7</sup>

To address this gap, semi-structured interviews were carried out with four barristers and six obstetric consultants practising in the UK.<sup>8</sup> The aim was to examine legal and clinical attitudes towards the updated